Clear Street raised the firm’s price target on Krystal Biotech (KRYS) to $288 from $217 and keeps a Buy rating on the shares. The firm says KB407 successfully induced wild-type CFTR protein expression in patient lung epithelial cells, at levels that are expected to be therapeutically meaningful.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Early Proof-of-Concept and Platform Potential Drive Buy Rating on Krystal Biotech Despite Pending Lung Function Data
- Krystal Biotech advances KB407 with positive CF trial data
- Krystal Biotech announces interim update from highest dose cohort of CORAL-1
- Krystal Biotech price target raised to $272 from $255 at BofA
- Krystal Biotech upgraded to Buy from Neutral at Citi